- Home
- TARS vs EVO Comparison
TARS vs EVO Comparison
Compare TARS & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- EVO
- Stock Information
- Founded
- TARS 2016
- EVO 1993
- Country
- TARS United States
- EVO Germany
- Employees
- TARS N/A
- EVO N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- TARS Health Care
- EVO Health Care
- Exchange
- TARS Nasdaq
- EVO Nasdaq
- Market Cap
- TARS N/A
- EVO 1.6B
- IPO Year
- TARS 2020
- EVO 2021
- Fundamental
- Price
- TARS $51.28
- EVO $3.29
- Analyst Decision
- TARS Strong Buy
- EVO Buy
- Analyst Count
- TARS 6
- EVO 2
- Target Price
- TARS $63.67
- EVO $5.90
- AVG Volume (30 Days)
- TARS 628.7K
- EVO 121.1K
- Earning Date
- TARS 05-07-2025
- EVO 05-21-2025
- Dividend Yield
- TARS N/A
- EVO N/A
- EPS Growth
- TARS N/A
- EVO N/A
- EPS
- TARS N/A
- EVO N/A
- Revenue
- TARS $182,953,000.00
- EVO $866,665,179.00
- Revenue This Year
- TARS $90.93
- EVO $3.70
- Revenue Next Year
- TARS $46.04
- EVO $10.32
- P/E Ratio
- TARS N/A
- EVO N/A
- Revenue Growth
- TARS 948.62
- EVO N/A
- 52 Week Low
- TARS $20.08
- EVO $2.85
- 52 Week High
- TARS $57.28
- EVO $7.98
- Technical
- Relative Strength Index (RSI)
- TARS 57.08
- EVO 29.96
- Support Level
- TARS $48.27
- EVO $3.38
- Resistance Level
- TARS $52.63
- EVO $3.63
- Average True Range (ATR)
- TARS 2.55
- EVO 0.09
- MACD
- TARS 0.58
- EVO -0.00
- Stochastic Oscillator
- TARS 79.89
- EVO 0.00
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.